Ceporex Paediatric Drops
Out of date information, search anotherSUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Ceporex Paediatric Drops Ceporex Syrup 500mg
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Cefalexin BP 500mg per 5ml (Cefalexin BP (in granules) 15.61% w/w, Cefalexin BP (in dispensed syrup) 10.00% w/v).
3 PHARMACEUTICAL FORM
Pale Orange Granules
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Ceporex is a bactericidal antibiotic of the cephalosporin group which is active against a wide range of Gram-positive and Gram-negative organisms. It is indicated for treatment of the following conditions, when caused by susceptible bacteria.
Respiratory tract infections: Acute and chronic bronchitis and infected bronchiectasis.
Ear, nose and throat infections: Otitis media, mastoiditis, sinusitis, follicular tonsillitis and pharyngitis.
Urinary tract infections: Acute and chronic pyelonephritis, cystitis and prostatitis. Prophylaxis of recurrent urinary tract infection.
Gynaecological and obstetric infections.
Skin, soft-tissue and bone infections.
Gonorrhoea (when penicillin is unsuitable).
Dental procedures: Treatment of dental infections.
4.2 Posology and method of administration
Route of administration: oral
Many infections in adults will respond to oral dosage of 1 gram to 2 grams per day in divided doses; however, for most infections, the following simple dosage scheme will be found satisfactory:
Adults and children over 12 years: 1g b.d.
The following additional information should also be considered:
Adults: For severe or deep-seated infections, especially when less sensitive organisms are involved, the dosage should be increased to 1g t.d.s. or 3g b.d. For prophylaxis of recurrent urinary tract infections in adults, a dose of 125mg each night is recommended and may be continued for several months (the 125mg/5ml Suspension is suitable for this purpose).
Children: Ideally, dosage should be calculated on a body-weight basis, particularly in infants. The following dosage recommendations for children are derived from a normal dosage of 25 to 60mg/kg/day. For chronic, severe or deep-seated infections, this should be increased to 100mg/kg/day (maximum 4g/day).
Children under 1 year (25 to 60mg/kg/day) 62.5 to 125mg b.d.
Children 1-6 years 250mg - 500mg b.d.
Children 7-12 years 500mg - 1 g b.d.
Notes: For most acute infections, treatment should continue for at least two days after signs have returned to normal and symptoms have subsided, but in chronic, recurrent or complicated urinary tract infections, treatment for two weeks (giving 1g b.d.) is recommended. For gonorrhoea, a single dose of 3g with 1g probenecid for males or 2g with 0.5g probenecid for females is usually effective. Concurrent administration of probenecid delays excretion of cefalexin and raises the serum levels by 50 to 100%.
Ceporex has not been shown to have a toxic effect on the kidney, but as with other antibiotics which are excreted mainly by the kidneys, unnecessary accumulation may occur in the body when renal function is below about half of normal. Therefore, the maximum recommended dosages (i.e. Adults 6g/day, children 4 g/day) should be reduced proportionately in these patients.
In elderly patients, the possibility of renal impairment should be considered.
Adult patients receiving intermittent dialysis should be given an additional 500mg Ceporex after each dialysis, i.e., a total dosage of up to 1g on that day. Children should receive an additional 8mg per kg.
4.3 Contraindications
Hypersensitivity to any ingredient of the preparation.
4.4 Special warnings and precautions for use
Special care is indicated in patients who have experienced an allergic reaction to penicillin or any other beta-lactams.
As with other broad-spectrum antibiotics, prolonged use may result in the overgrowth of non-susceptible organisms (e.g. Candida, Enterococci, Clostridium difficile), which may require interruption of treatment. Pseudomembranous colitis has been reported with the use of broad-spectrum antibiotics, therefore, it is important to consider its diagnosis in patients who develop severe diarrhoea during or after antibiotic use, see section 4.8.
As with other antibiotics that are excreted mainly by the kidneys, when renal function is poor, dosage of Ceporex should be suitably reduced (see Posology and method of administration).
Ceporex is not thought to be porphyrinogenic as it is not metabolised and is excreted unchanged in the urine. Nevertheless, caution is advised when prescribing this product to a patient suffering from porphyria.
In patients receiving Ceporex, a false-positive reaction for glucose in the urine may be given, with Benedict's or Fehling's solution, or with 'Clinitest' tablets, but not with enzyme-based tests.
There may be a positive reaction to the Coomb’s test while taking cefalexin but haemolytic anaemia rarely occurs.
4.5 Interaction with other medicinal products and other forms of interaction
Concurrent treatment with high doses of cephalosporins and nephrotoxic drugs such as aminoglycosides or potent diuretics (e.g. furosemide, ethacrynic acid and piretamide) may adversely affect renal function. Clinical experience has shown that it is not likely to be a problem with Ceporex at the recommended dosage levels.
Hypokalaemia has been described in patients taking cytotoxic drugs for leukaemia when they were given gentamicin and cefalexin.
One or two cases of combined oral contraceptive failure have been attributed to concurrent treatment with cefalexin. It is advisable for patients to use an alternative method of non-hormonal contraception, such as a condom, during a short course treatment of less than three weeks and for seven days following treatment with cefalexin.
Probenecid inhibits the excretion of cefalexin leading to increased serum levels and a prolonged half-life.
Ceporex can interfere with the alkaline picrate assay for creatinine, giving a falsely high reading, but the degree of elevation is unlikely to be of clinical importance.
In a single study of 12 healthy subjects given single 500mg doses of cefalexin and metformin, maximum serum levels and AUC increased by an average of 34% and 24%, respectively. Metformin renal clearance decreased by an average of 14%. No side-effects were reported in the 12 healthy subjects in this study. No information is available about the interaction of cefalexin and metformin following multiple dose administration of in long term use. The clinical significance of this study is unclear.
4.6 Pregnancy and lactation
Laboratory experiments and clinical experience show no evidence of teratogenicity, but it would be wise to proceed with caution during the early months of pregnancy, as with all drugs.
Cefalexin is excreted in human milk in low concentrations and should be used with caution in nursing mothers.
4.7 Effects on ability to drive and use machines
Cefalexin may cause dizziness. Patients should be warned not to drive or operate machinery until the effect of cefalexin has been established.
4.8 Undesirable effects
Blood and Lymphatic System Disorders:
Adverse effects common to the cephalosporin group are the blood and lymphatic system disorders: eosinophilia, thrombocytopenia, leucopenia, neutropenia to agranulocytosis, and aplastic anaemia. Haemolytic anaemia has been reported but rarely occurs.
Cefalexin does not contain an N-methylthiotetrazole side chain and therefore the risk of bleeding complications due to impaired vitamin-K dependent clotting factor synthesis is low.
Nervous System
Disorders:
Nervous system disorders that have been reported are headache, dizziness, confusion, hallucinations, hyperactivity, nervousness, sleep disturbances. Patients should be advised not to drive or use machinery if they feel dizzy after taking Ceporex, see Section 4.7.
There are some reports of patients suffering from hypertonia after cephalosporin treatment.
Gastrointestinal
Disorders:
Gastrointestinal adverse effects such as nausea, vomiting, abdominal discomfort and diarrhoea have been reported. Dyspepsia has also occurred. As with other broad-spectrum antibiotics, prolonged use may result in the overgrowth of non-susceptible organisms and pseudomembranous colitis may develop. There has been some evidence from clinical trials of some cephalosporins that the incidence of diarrhoea and pseudomembranous colitis are dose related and therefore the Committee for the Safety of Medicines has recommended that higher doses should be reserved for severe infections and that in any case, treatment should be discontinued if symptoms suggestive of pseudomembranous colitis arise.
Cephalosporins may cause disturbances in liver enzymes, transient hepatitis and cholestatic jaundice. Normal liver function should return following discontinuation of the medication.
Renal and Urinary Disorders:
Reversible interstitial nephritis has occurred in a few patients but this is very rare. Acute renal tubular necrosis has followed excessive dosage and has also been associated with use in older patients and in patients with renal impairment, See Section 4.2.
As with other antibiotics, prolonged use may result in the overgrowth of non- susceptible organisms, e.g., Candida. This may present as vulvovaginitis.
Hypersensitivity
Reactions:
Hypersensitivity reactions have been associated with the use of all cephalosporins, including cefalexin. These reactions include: urticarial and maculopapular rashes, erythema multiforme and allergic pruritus, toxic epidermal necrolysis, Stevens-Johnson syndrome, angioedema and anaphylaxis, serum-sickness-like reactions e.g. skin rash, hives, itching, joint pain, fever, malaise, enlarged lymph nodes.
4.9 Overdose
Serum levels of cefalexin can be reduced greatly by peritoneal dialysis or haemodialysis.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Bacteriology:
Cefalexin is a bactericidal antibiotic of the cephalosporin group which is active against a wide range of Gram-positive and Gram-negative organisms. The bactericidal activity is due to inhibition of bacterial wall synthesis of actively dividing cells by binding to essential target proteins, penicillin binding proteins (PBPs). Cefalexin also decreases the availability of murein hydrolase, an enzyme essential for cell division, and therefore preventing bacterial cell division.
Breakpoints:
The following MIC breakpoints for cefalexin 500mg oral dose, separating susceptible (S) from resistant(R) micro-organisms have been provided by a report from the British Society of Antimicrobial Chemotherapy Working Party (J Antimicrob Chemo 1991; Suppl D to Vol 27):
Staphylococcus aureus: S<=8mcg/ml, R >8mcg/ml
Streptococci: S<=2mcg/ml, R >2mcg/ml
Enterobacteriacae: S<=8mcg/ml, R >8mcg/ml
Susceptibility:
The prevalence of resistance may vary geographically and with time for selected species. Local information on resistance is desirable, particularly when treating severe infections. This information gives only an approximate guidance on the probabilities whether micro-organisms will be susceptible to cefalexin or not. The following table lists the susceptibilities of various bacteria:
|
Susceptible |
Range of acquired |
|
resistance in UK |
|
Aerobic Gram-positive micro-organisms | |
|
Staphylococcus aureus-methicillin susceptible strains |
<1% |
|
Staphylococcus epidermidis (methicillin susceptible) |
<1% |
|
Streptococcus agalactiae |
0% |
|
Streptococcus pneumoniae |
4% |
|
Streptococcus pyogenes |
0% |
|
Viridans group Streptococcus |
Not known |
|
Aerobic Gram-negative micro-organisms | |
|
Escherichia coli |
3% |
|
Haemophilus influenzae |
Not known |
|
Klebsiella species |
7% |
|
Neisseria gonorrhoeae |
Not known |
|
Proteus mirabilis |
5% |
|
Resistant | |
|
Aerobic Gram-positive micro-organisms | |
|
Staphylococcus aureus-methicillin resistant |
100% |
|
Aerobic Gram-negative micro-organisms | |
|
Citrobacter freundii |
>50% |
|
Enterobacter aerogenes |
>50% |
|
Enterobacter cloacae |
>50% |
|
Enterococcus faecalis |
100% |
|
Morganella morganii |
>50% |
|
Pseudomonas aeruginosa |
100% |
Other information:
Certain micro-organisms which are resistant to first and second generation cephalosporins and to other beta-lactam antibiotics may exhibit resistance to cefalexin.
5.2 Pharmacokinetic properties
Absorption
Cefalexin is almost completely absorbed in the upper portions of the gastrointestinal tract. Following oral administration, absorption is rapid and peak serum levels (4.5pg/ml for a 125mg dose, 9pg/ml for 250mg dose, 18pg/ml for a 500mg dose and 32pg/ml for a 1000mg dose) are usually reached at one hour. In patients with normal renal function, serum levels persist for 4 to 6 hours and disappear within 8 hours. Absorption is delayed when cefalexin is given with or shortly after food, but the total amount absorbed is not altered.
Absorption of cefalexin is not adversely affected by coeliac disease, partial gastrectomy, achlorhydria, jaundice or diverticulosis (duodenal or jejunal).
The serum half-life is normally about one hour, but is longer in the newborn (see Dosage and Administration).
In patients with impaired renal function, an increase in serum half-life of cefalexin occurs. Clinical practice indicates that in view of the wide therapeutic window of cefalexin, the standard recommended doses should be halved only in those patients with creatinine clearance < 50ml/min. The maximum recommended dose (i.e. adults 6g/day, children 4g/day) should be reduced to 50% in mild (40 - < 50ml/min), 25% in moderate (>10 - < 40 ml/min) and 12.5% in severe renal impairment (< 10ml/min).
Distribution
Cefalexin is widely distributed in body tissues and high concentrations are found in all organs, particularly the liver and kidneys. Cefalexin reaches therapeutic levels in the blood, urine, bile, synovial fluid, tonsillar tissue, amniotic fluid, cord blood and foetal blood.
Metabolism and Elimination
Cefalexin is not metabolised in the body and is rapidly excreted unchanged in the urine. High concentrations (80-100%) of an orally administered dose are recoverable in the urine within 6 to 8 hours. Cefalexin is excreted in human milk in low concentrations.
Concurrent administration of probenecid delays excretion of cefalexin and raises serum levels by 50 to 100% (see Sections 4.2 and 4.5 of this SPC).
5.3 Preclinical safety data
Cefalexin is not anticipated to cause any genotoxic or carcinogenic effects, although no specific studies have been performed to determine this.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
In Granules & Dispensed Syrup
Sodium Calcium Edetate Acacia Powdered Citric Acid Sodium Citrate
Sunset Yellow Ariavit (311831) E110 Polvaromas Orange-Bramble Flavour Sucrose Purified water
6.2 Incompatibilities
No incompatibilities have been reported.
6.3 Shelf Life
Dispensed Syrup: 24 months (unopened), 10 days when the bottle container is opened for the first time.
6.4 Special precautions for storage
Amber glass bottles
24 months at a temperature not exceeding 25°C.
Store the constituted syrup at 2°C - 8°C, in a refrigerator.
HDPE bottles
36 months at a temperature not exceeding 25°C.
Store the constituted syrup at 2°C - 8°C, in a refrigerator.
6.5 Nature and contents of container
Bottles: 150ml amber glass bottles with PVC lined aluminium roll on caps or polypropylene caps having caps having Melinex/Aluminium pulpboard liners.
Pack size: 100ml.
15ml amber glass bottles with a white screw cap and polycone liner, together with a plastic dropper assembly, rubber teat and polypropylene screw cap.
Pack size: 10ml.
Bottles: 150ml high density polyethylene (HDPE) bottles with tamper-evident polypropylene caps with polyethylene (PE) liners.
Pack size:100ml.
6.6 Special precautions for disposal
150ml Glass and plastic (HDPE) bottles
To reconstitute, slowly add 60ml of water, replace cap and shake well. Upon reconstitution a uniform orange suspension with a characteristic odour is produced.
Ceporex Paediatric Drops
To reconstitute, slowly add 60ml of water, replace cap and shake well. Discard cap and fit dropper. Upon reconstitution a uniform orange suspension with a characteristic odour is produced.
7 MARKETING AUTHORISATION HOLDER
Co-Pharma Limited,
Unit 4, Metro Centre, Tolpits Lane Watford Herts
WD18 9SS
8 MARKETING AUTHORISATION NUMBER(S)
PL 13606/0171
9 DATE OF FIRST AUTHORISATION
December 1969
10 DATE OF REVISION OF THE TEXT
25/03/2015